Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OPDIVO 600 MG SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/OPDIVO 600 MG SOLUCION INYECTABLE

Approved

STANDARD

OPDIVO 600 MG SOLUCION INYECTABLE

Bristol-Myers Squibb Pharma Eeig🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 13, 2025
Approval ID: 9fb17e37f6c68b62
Company: Bristol-Myers Squibb Pharma Eeig
Type: Standard

Approval Details

Approval Id: 9fb17e37f6c68b62
Drug Cima Aemps Name: OPDIVO 600 MG SOLUCION INYECTABLE
Register Number: 1151014005
Holder Company Name: Bristol-Myers Squibb Pharma Eeig
Marketing Company Name: Bristol Myers Squibb S.A.
Holder Company Detail Path: /organization/f30e164d1ccf693f/bristol-myers-squibb-pharma-eeig
Authorization Date: 2025-06-13
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 600 mg
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Bristol-Myers Squibb Pharma Eeig
Company Detail Path: /organization/f30e164d1ccf693f/bristol-myers-squibb-pharma-eeig

Company Information

Pharmaceutical Company Name: Bristol-Myers Squibb Pharma EEIG
Country Name: Ireland

Active Ingredients

NIVOLUMAB

600 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 13, 2025

Approval ID

9fb17e37f6c68b62

Type

Standard

Back to CIMA-AEMPS Approvals